Clinical trial
A Randomized, Controlled, Multicenter Study To Evaluate the Safety and Efficacy of Tocilizumab In Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
NCT06452537 is registered in ClinicalTrials.gov with Tianjin Medical University General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Controlled, Multicenter Study To Evaluate the Safety and Efficacy of Tocilizumab In Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
- Lead sponsor
- Tianjin Medical University General Hospital
- Phase
- Phase 2/3
- Overall status
- Active, not recruiting
- Start date
- July 9, 2024
- Completion date
- July 1, 2026
- Enrollment
- 102 (estimated)
- Sites
- 22
Conditions
As the registry lists them; a condition with its own page is linked.